Ningxia Zhongke Biotechnology Co., Ltd.
600165.SS · SHH
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | CN¥1,663,969 | CN¥2,341,222 | CN¥4,629,814 | CN¥9,197,989 |
| - Cash | CN¥8,607 | CN¥24,399 | CN¥89,484 | CN¥110,953 |
| + Debt | CN¥227,897 | CN¥559,295 | CN¥984,659 | CN¥916,519 |
| Enterprise Value | CN¥1,883,260 | CN¥2,876,117 | CN¥5,524,990 | CN¥10,003,555 |
| Revenue | CN¥345,318 | CN¥285,689 | CN¥681,134 | CN¥192,387 |
| % Growth | 20.9% | -58.1% | 254% | – |
| Gross Profit | -CN¥67,470 | -CN¥134,608 | CN¥75,688 | CN¥23,893 |
| % Margin | -19.5% | -47.1% | 11.1% | 12.4% |
| EBITDA | -CN¥306,265 | -CN¥235,172 | CN¥48,961 | -CN¥134,502 |
| % Margin | -88.7% | -82.3% | 7.2% | -69.9% |
| Net Income | -CN¥538,907 | -CN¥465,506 | -CN¥170,109 | -CN¥29,947 |
| % Margin | -156.1% | -162.9% | -25% | -15.6% |
| EPS Diluted | -0.79 | -0.68 | -0.25 | -0.044 |
| % Growth | -16.2% | -172% | -472.1% | – |
| Operating Cash Flow | -CN¥85,192 | CN¥23,154 | CN¥53,144 | -CN¥7,769 |
| Capital Expenditures | -CN¥6,202 | -CN¥57,682 | -CN¥59,310 | -CN¥250,555 |
| Free Cash Flow | -CN¥91,394 | -CN¥34,528 | -CN¥6,165 | -CN¥258,324 |